- Home
- WAL vs VTRS Comparison
WAL vs VTRS Comparison
Compare WAL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAL
- VTRS
- Stock Information
- Founded
- WAL 1994
- VTRS 1961
- Country
- WAL United States
- VTRS United States
- Employees
- WAL N/A
- VTRS N/A
- Industry
- WAL Major Banks
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- WAL Finance
- VTRS Health Care
- Exchange
- WAL Nasdaq
- VTRS Nasdaq
- Market Cap
- WAL 7.8B
- VTRS 9.0B
- IPO Year
- WAL 2005
- VTRS N/A
- Fundamental
- Price
- WAL $74.45
- VTRS $8.77
- Analyst Decision
- WAL Strong Buy
- VTRS Hold
- Analyst Count
- WAL 15
- VTRS 4
- Target Price
- WAL $95.33
- VTRS $10.50
- AVG Volume (30 Days)
- WAL 1.0M
- VTRS 13.4M
- Earning Date
- WAL 04-21-2025
- VTRS 05-08-2025
- Dividend Yield
- WAL 2.04%
- VTRS 5.41%
- EPS Growth
- WAL 6.13
- VTRS N/A
- EPS
- WAL 7.28
- VTRS N/A
- Revenue
- WAL $3,049,400,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- WAL $13.35
- VTRS N/A
- Revenue Next Year
- WAL $9.86
- VTRS $1.20
- P/E Ratio
- WAL $10.23
- VTRS N/A
- Revenue Growth
- WAL 11.37
- VTRS N/A
- 52 Week Low
- WAL $56.70
- VTRS $6.85
- 52 Week High
- WAL $98.10
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- WAL 57.81
- VTRS 57.48
- Support Level
- WAL $70.45
- VTRS $8.47
- Resistance Level
- WAL $75.71
- VTRS $9.57
- Average True Range (ATR)
- WAL 2.49
- VTRS 0.30
- MACD
- WAL 1.03
- VTRS 0.15
- Stochastic Oscillator
- WAL 90.51
- VTRS 59.39
About WAL Western Alliance Bancorporation (DE)
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.